Accomplished pharmaceutical executive with a passion for discovering innovative therapeutics to address unmet medical needs. Over 30 years of industrial experience focused on small molecule and peptide drug discovery across therapeutic areas leading to over 40 development candidates, including JANUVIA® (sitagliptin), a treatment for patients with Type 2 diabetes (T2DM), MARIZEV® (omarigliptin), a once-weekly treatment for T2DM approved in Japan, and GEMTESA® (vibegron) for the treatment of patients with overactive bladder. Highly collaborative scientific leader in drug discovery and early development, recognized for building strong teams, setting strategy and managing change. Noted for strong interpersonal skills, talent development, and commitment to advancing women in science.